Pathalys Pharma

Pathalys Pharma, Inc. is a private, late-stage biopharmaceutical company focused on developing innovative therapies for patients with chronic kidney disease (CKD). They are committed to addressing unmet needs in the management of end-stage kidney disease (ESKD), particularly focusing on the development of enhanced therapeutics that improve the management of CKD. Their primary asset is upacicalcet, a novel calcimimetic with the potential to improve the treatment of secondary hyperparathyroidism (SHPT) in hemodialysis patients.

Pathalys has garnered significant investment, including a $105 million Series B financing round, to advance their development program. They are headquartered in Research Triangle Park, North Carolina and have forged strategic partnerships with organizations like Launch Therapeutics to accelerate their clinical trials and pre-commercialization efforts. The company actively presents at industry conferences and seeks to bring their potential treatments to market to benefit patients with ESKD.

Pathalys Pharma is a private, late-stage clinical biopharmaceutical company focused on improving the lives of patients with chronic kidney disease (CKD). They are dedicated to developing innovative therapeutics that address unmet needs in the management of CKD, particularly end-stage kidney disease (ESKD). Their primary asset, upacicalcet, is a novel calcimimetic with the potential to significantly improve the treatment of secondary hyperparathyroidism (SHPT) in hemodialysis patients. Beyond upacicalcet, Pathalys continues to identify and pursue solutions for patients with ESKD.

Pathalys Pharma fosters a culture that is highly motivated and driven by a shared commitment to improving the lives of patients with chronic kidney disease. The company emphasizes the importance of teamwork, collaboration, and innovation in the development and advancement of therapeutic treatments, reflecting a strong dedication to achieving positive outcomes for those living with ESKD.